Lv3
340 积分 2024-03-01 加入
Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis
3个月前
已完结
Trends in use of poly (ADP-ribose) polymerase inhibitor (PARPi) in ovarian cancer
5个月前
已关闭
Chemoresistance in ovarian cancer (I)
5个月前
已关闭
PARP inhibitor maintenance treatment for newly diagnosed ovarian cancer patients: a real-world study from China
7个月前
已完结
Effectiveness of PARP inhibitor maintenance therapy in ovarian cancer by BRCA1/2 and a scar-based HRD signature in real-world practice
7个月前
已完结
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from PRIMA/ENGOT-OV26/GOG-3012 trial
10个月前
已完结
Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort
10个月前
已完结
[Real-world clinical data analysis of PARPi as first-line maintenance therapy in newly diagnosed epithelial ovarian cancer patients]
10个月前
已完结
Mechanism of Action of PARP Inhibitors
10个月前
已完结
Incorporating immune checkpoint inhibitors in epithelial ovarian cancer
10个月前
已完结
皖公网安备34019202002308
